Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

321182 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-31

Study Completion Date

2018-12-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the risk of major bleeding event among nonvalvular atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

NCT03189069

Atrial Fibrillation

COMPLETED

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

NCT04297150

Atrial Fibrillation

UNKNOWN

Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

NCT02792335

Atrial Fibrillation

COMPLETED

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

NCT02769078

Atrial Fibrillation

COMPLETED

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.

NCT03715725

Non-valvular Atrial Fibrillation

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients using Warfarin

Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Warfarin

Warfarin

Intervention Type DRUG

Patients using Apixaban

Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Apixaban

Apixaban

Intervention Type DRUG

Patients using Dabigatran

Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Dabigatran

Dabigatran

Intervention Type DRUG

Patients using Rivaroxaban

Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Rivaroxaban

Rivaroxaban

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Warfarin

Intervention Type DRUG

Apixaban

Intervention Type DRUG

Dabigatran

Intervention Type DRUG

Rivaroxaban

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ≥18 years old as of the index date
* At least 1 diagnosis of atrial fibrillation in the 12 months prior to or on index date, identified by any medical claim
* At least one year of baseline period and continuous enrollment for at least 12 months prior to index date Individuals with NVAF who were using oral anticoagulants (i.e., warfarin, dabigatran, rivaroxaban and apixaban) within the study period beginning Jan 1, 2012 through December 31, 2013 or last date of the last data cut available at the time of execution of the study

Exclusion Criteria

* Patients with evidence of valvular heart disease, thyrotoxicosis, pericarditis, mitral stenosis, Venous thromboembolism(VTE), heart surgery, and endocarditis during the baseline period any time prior to or on index date
* Patients with any evidence of pregnancy at any time during the baseline will be excluded

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No